Last reviewed · How we verify

NCT03642522

Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI

Completed NA Last updated 12 January 2021
What this trial tests

NA trial testing repetitive transcranial magnetic stimulation in Major Depressive Disorder in 72 participants. Completed in 1 August 2020.

Timeline
1 November 2018
Primary endpoint
30 March 2020
1 August 2020

Quick facts

Lead sponsorUniversity of British Columbia
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment72
Start date1 November 2018
Primary completion30 March 2020
Estimated completion1 August 2020
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

University of British Columbia

Who can join

Adults 18 to 80, any sex, with Major Depressive Disorder or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is identify biomarkers of response to repetitive transcranial magnetic stimulation (rTMS) in individuals with first episode or treatment resistant depression. These biomarkers include simultaneous TMS-fMRI (functional magnetic resonance imaging), a blood smear, cognitive and behavioural assessments, questionnaires, and neurophysiology.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of repetitive transcranial magnetic stimulation

Trials testing the same drug.

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

Other University of British Columbia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03642522.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing